PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Saneca Pharma appoints new CEO

 Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král.
 
Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked for GlaxoSmithKline and Zentiva Group across the Central and Eastern Europe (CEE) and the Commonweath of Independent States (CIS) regions and has over 17 years’ experience in the pharmaceutical sector and FMCG.
 
As CEO, he will be responsible for implementing Saneca’s business growth strategy, driving operational efficiency and ensuring effective project delivery across the business.
 
Richard Král said: “I am delighted to be appointed as CEO of Saneca. Over the last three years I have developed a comprehensive understanding of the company and I am looking forward to continuing to drive its success and establishing Saneca as the go-to CDMO in Europe.
 
“I have a lot of experience in the CEE market, where Saneca is based, and the CDMO’s technical agility and ability to cater for the entire drug life cycle really set it apart from its competitors. We intend to continue our strong growth as we progress through 2018 and it will be extremely rewarding to see the company continue to expand in my new position as CEO.”
 
Based in western Slovakia, in close proximity to Vienna, Saneca Pharma offers its customers strong capabilities in solids, semi-solids and liquids, as well as specialist expertise in the development and manufacture of opiate active pharmaceutical ingredients (APIs) and finished dosage forms from farm to pharmacy.
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026